Company Overview and News
Nabors Industries (NBR - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
In a bid to further cement its market position, Canada’s largest drilling contractor Precision Drilling Corporation (PDS - Free Report) is set to acquire its peer Trinidad Drilling Limited, the third largest driller in the nation, in a deal worth C$1.03 billion. Notably, Precision Drilling would make up for approximately 30% of the contract drilling market in Canada, following the acquisition. Interestingly, the combined company will become the third largest driller in North America in terms of rig count, on par with Nabors Industries Limited (NBR - Free Report) , while remaining just behind Helmerich and Payne Inc.
WRG WEEEF MEG HUSKF PDS NBR SPE HSE TDGCF PTEN MEGEF BTE SVGYF SVY TOTZF PTORF TDG
RPC, Inc. (RES) provides specialized oilfield services and equipment primarily to the E&P producers in the U.S. and the international markets. Limited margin expansion and the Permian capacity constraint issue will keep RES’s growth muted in the next couple of quarters. However, in the medium-to-long term, the energy market’s growth will take over the short-term headwind and will accelerate growth for RES.
BHI TRI NBR
2018-09-20 seekingalpha - 1
As oil prices stay above $55/barrel and companies make drilling plans for next year, the subdued price levels of oilfield service company stocks could make them good investments.
HAL BHI PTEN SLB GEC GE WFT BHGE GNE SLB NBR
It has been hard for investors to make some of the same gains in the oil and gas segment since oil prices have recovered handily. That may be about to change, or at least that is the take of Morgan Stanley. The firm issued a series of major upside calls for its clients looking to profit within oil and gas.
WFCNP HAL MS RIG WFC SLB BHGE NBR DO DRQ BHI TRI SCL SLB SGAZF
While most of Wall Street focuses on large and mega-cap stocks, which provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the low to mid hundreds, all the way up to over $1,000 per share. At those steep prices, it’s pretty hard to get any decent share count leverage.
It has been about a month since the last earnings report for Nabors Industries (NBR - Free Report) . Shares have lost about 0.8% in that time frame, underperforming the S&P 500.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NBR / Nabors Industries Ltd. on message board site Silicon Investor.
as of ET